KTRA RSI Chart
Last 7 days
-6.7%
Last 30 days
40%
Last 90 days
40%
Trailing 12 Months
-95.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2014 | 0 | 0 | 0 | 0 |
2013 | 0 | 13.8K | 8.9K | 5.7K |
2012 | 11.4K | 11.6K | 12.3K | 13.1K |
2011 | 0 | 10.7K | 10.9K | 11.1K |
2010 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 01, 2023 | hoffman robert e. | acquired | - | - | 59,800 | president, ceo, and cfo |
Jan 05, 2023 | brown dennis m | acquired | - | - | 363 | chief scientific officer |
Aug 01, 2022 | hoffman robert e. | acquired | - | - | 400,145 | president and ceo |
Aug 01, 2022 | brown dennis m | acquired | - | - | 240,087 | chief scientific officer |
Aug 01, 2022 | praill anthony scott | acquired | - | - | 240,087 | chief financial officer |
Feb 15, 2022 | hoffman robert e. | bought | 25,795 | 0.469 | 55,000 | president and ceo |
Dec 08, 2021 | praill anthony scott | bought | 19,429 | 0.677 | 28,700 | chief financial officer |
Dec 07, 2021 | zarrabian saiid | bought | 24,298 | 0.6376 | 38,109 | head of strategic partnerships |
Dec 06, 2021 | zarrabian saiid | bought | 7,018 | 0.5902 | 11,891 | head of strategic partnerships |
Nov 22, 2021 | johnson laura l. | bought | 2,226 | 0.7423 | 3,000 | - |
Which funds bought or sold KTRA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 7,214 | 7,214 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | -703 | 1,115 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 277 | 1,079 | 1,904 | -% |
May 15, 2024 | Nantahala Capital Management, LLC | reduced | -71.02 | -6,185 | 1,285 | -% |
May 14, 2024 | Qube Research & Technologies Ltd | new | - | 686 | 686 | -% |
May 13, 2024 | UBS Group AG | new | - | 14,418 | 14,418 | -% |
May 13, 2024 | HRT FINANCIAL LP | new | - | 8,000 | 8,000 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | -2,832 | 4,489 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 100 | 1.00 | 3.00 | -% |
May 10, 2024 | ACADIAN ASSET MANAGEMENT LLC | reduced | -99.73 | -21,000 | - | -% |
Unveiling Kintara Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Kintara Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Kintara Therapeutics, Inc. News
Income Statement (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2014Q1 | 2013Q4 | 2013Q3 | 2013Q2 | 2012Q4 | 2012Q3 | 2012Q2 | 2012Q1 | 2011Q4 | 2011Q3 | 2011Q2 | 2011Q1 | 2010Q4 | 2010Q3 |
Revenue | -100.0% | - | 620 | 691 | 1,180 | 3,250 | 3,780 | 5,623 | 6,175 | 6,726 | 3,162 | 250 | 6,872 | 13,493 | 6,410 |
Costs and Expenses | - | - | - | - | - | - | - | - | - | 10,916 | 3,858 | - | - | 14,568 | 7,910 |
Interest Expenses | 198.6% | 2,015 | -2,044 | -2,029 | 1,992 | 1,886 | 1,900 | 1,876 | 1,864 | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 295.0% | 7,446 | 1,885 | 1,477 | 3,979 | 6,740 | 9,917 | 13,210 | 15,948 | 12,798 | 17,718 | 22,343 | 13,543 | 18,853 | 20,489 | 23,131 | 2,938 | 5,102 | 6,508 | 8,364 | 4,037 | 2,457 |
Current Assets | 469.6% | 6,755 | 1,186 | 783 | 3,270 | 6,016 | 9,178 | 8,156 | 13,258 | 10,093 | 14,998 | 20,108 | 11,793 | 16,588 | 17,717 | 22,955 | 2,851 | 5,099 | 6,502 | 8,354 | 4,025 | 2,442 |
Cash Equivalents | 865.2% | 6,351 | 658 | 216 | 1,535 | 3,045 | 4,874 | 7,085 | 11,780 | 8,839 | 14,064 | 19,339 | 10,537 | 15,718 | 17,158 | 22,602 | 2,392 | 4,973 | 6,348 | 8,060 | 3,719 | 2,152 |
Net PPE | -1.1% | 691 | 699 | 694 | 709 | 724 | 739 | 754 | 90.00 | 105 | 120 | 135 | 150 | 165 | 172 | 175 | 2.00 | - | - | - | - | - |
Liabilities | -25.6% | 1,524 | 2,049 | 3,503 | 3,248 | 2,954 | 3,319 | 3,592 | 4,153 | 3,412 | 3,616 | 3,180 | 2,962 | 2,735 | 2,904 | 2,577 | 2,675 | 1,382 | 1,027 | 1,339 | 2,070 | 1,198 |
Current Liabilities | -28.3% | 1,341 | 1,870 | 3,336 | 3,082 | 2,790 | 3,239 | 3,516 | 3,990 | 3,240 | 3,438 | 3,001 | 2,780 | 2,533 | 2,727 | 2,389 | 2,675 | - | - | - | 2,070 | 1,198 |
Shareholder's Equity | 3711.0% | 5,922 | -164 | -2,026 | 731 | 3,786 | 6,598 | 9,618 | 11,795 | 9,386 | 14,102 | 19,163 | 10,581 | 16,118 | 17,585 | 20,554 | 263 | 3,721 | 5,481 | 7,025 | 1,968 | 1,259 |
Retained Earnings | -1.3% | -157,550 | -155,537 | -154,512 | -151,375 | -148,038 | -144,772 | -141,316 | -136,356 | -130,908 | -125,550 | -119,655 | -111,225 | -104,489 | -97,846 | -92,427 | -69,721 | -65,893 | -63,933 | -62,188 | -60,578 | -57,988 |
Additional Paid-In Capital | 5.6% | 153,144 | 145,090 | 141,855 | 141,438 | 141,156 | 140,571 | 138,278 | 135,575 | 127,670 | 126,781 | 125,074 | 106,821 | 100,828 | 93,551 | 89,777 | 65,148 | 56,395 | 56,264 | 56,098 | 50,955 | 47,022 |
Shares Outstanding | - | - | - | - | 1,620 | 1,596 | 1,554 | 1,464 | 974 | 879 | 828 | 686 | 518 | 585 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | 12.00 | - | - | - | 24,700 | - | - | - | 26,900 | - | - | - | 7,700 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -8.6% | -2,300 | -2,117 | -1,317 | -1,508 | -1,827 | -2,161 | -6,369 | -4,992 | -5,223 | -5,104 | -5,073 | -4,689 | -4,630 | -5,431 | -4,110 | -2,578 | -1,373 | -1,711 | -2,266 | -1,812 | -1,464 |
Share Based Compensation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 96.00 | 160 | 51.00 | 71.00 | 100 |
Cashflow From Investing | - | - | - | - | - | - | - | -232 | - | - | - | - | - | -8.00 | 3.00 | 969 | - | - | - | - | - | - |
Cashflow From Financing | 209.9% | 7,993 | 2,579 | -2.00 | -2.00 | -2.00 | -50.00 | 1,906 | 7,933 | -2.00 | -171 | 13,875 | -492 | 3,198 | -16.00 | 23,351 | -3.00 | -2.00 | -1.00 | 6,607 | 3,379 | -85.87 |
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
Expenses | ||||
Research and development | $ 592 | $ 2,005 | $ 2,562 | $ 7,235 |
General and administrative | 1,493 | 1,297 | 3,504 | 4,212 |
Operating expenses | (2,085) | (3,302) | (6,066) | (11,447) |
Other income (loss) | ||||
Foreign exchange | 0 | (1) | (8) | 10 |
Interest, net | 74 | 39 | 78 | 123 |
Other income (loss) | 74 | 38 | 70 | 133 |
Net loss for the period | (2,011) | (3,264) | (5,996) | (11,314) |
Computation of basic loss per share | ||||
Net loss | (2,011) | (3,264) | (5,996) | (11,314) |
Series A Preferred cash dividend | (2) | (2) | (6) | (6) |
Net loss for the period attributable to common stockholders | $ (2,013) | $ (3,266) | $ (6,175) | $ (11,682) |
Basic and fully diluted loss per share | $ (0.05) | $ (1.94) | $ (0.37) | $ (7.32) |
Basic and fully diluted weighted average number of shares | 44,562,000 | 1,681,000 | 16,772,000 | 1,596,000 |
Preferred Stock Series C | ||||
Computation of basic loss per share | ||||
Preferred stock dividend | $ (173) | $ (362) |
Condensed Consolidated Interim Balance Sheet - USD ($) $ in Thousands | Mar. 31, 2024 | Jun. 30, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 6,351 | $ 1,535 |
Prepaid expenses, taxes and other receivables | 208 | 660 |
Clinical trial deposit | 196 | 1,075 |
Total current assets | 6,755 | 3,270 |
Property and equipment, net | 691 | 709 |
Total assets | 7,446 | 3,979 |
Current liabilities | ||
Accounts payable and accrued liabilities | 1,243 | 2,784 |
Total current liabilities | 1,341 | 3,082 |
Milestone payment liability | 183 | 166 |
Total liabilities | 1,524 | 3,248 |
Stockholders' equity | ||
Common stock Authorized 75,000 shares at March 31, 2024 (June 30, 2023 - 75,000), $0.001 par value Issued and outstanding 55,305 issued at March 31, 2024 (June 30, 2023 - 1,692) | 55 | 2 |
Additional paid-in capital | 153,144 | 141,438 |
Accumulated deficit | (157,550) | (151,375) |
Accumulated other comprehensive income | 21 | 21 |
Total stockholders' equity | 5,922 | 731 |
Total liabilities and stockholders' equity | 7,446 | 3,979 |
Related Party | ||
Current liabilities | ||
Related party payables | 98 | 298 |
Preferred Stock Series A | ||
Stockholders' equity | ||
Preferred stock | 279 | 279 |
Preferred Stock Series C | ||
Stockholders' equity | ||
Preferred stock | $ 9,973 | $ 10,366 |